FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Malaria | Vaccine

Glaxo promises "sustainable" malaria vax price

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools
  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

Glaxo's Andrew Witty says he'll price the company's new malaria vaccine just over cost. And any profits, he pledges, will be plowed back into research. Analysts say that more than $500 million has been spent advancing the new vaccine through the pipeline. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Malaria   Vaccine